Healthcare & Life Sciences
Yellowstone Biosciences
United Kingdom
series-a
series-a
Stage
1
Investors
About
Yellowstone Biosciences develops soluble T-cell receptor (TCR)-based biologic therapies focused on treating cancers, particularly acute myeloid leukaemia.
Explore Yellowstone Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.